Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for unmet medical needs in liver diseases and viral infections, specifically chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections ¹. The company's core business model involves generating revenue through collaboration agreements and customer contracts for research and development services, rather than product sales, as it currently has no approved commercial products ².

The company's pipeline includes three clinical-stage drug candidates: pevifoscorvir sodium for chronic HBV infection, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections, along with a portfolio of preclinical programs ³. Pevifoscorvir sodium is a potential best-in-class Capsid Assembly Modulator (CAM-E) for chronic HBV infection, which has demonstrated enhanced pharmacologic properties and greater HBV DNA suppression in preclinical testing compared to standard of care nucleos(t)ide analogs (NAs), and multi-log 10 reductions in viral antigens in Phase 1 clinical trials ⁴. ALG-055009 is a potential best-in-class thyroid hormone receptor beta (THR-β) agonist for MASH and obesity, showing enhanced pharmacologic properties compared to competitor THR-β agonists, with Phase 2a topline data demonstrating statistically significant reductions in liver fat at Week 12 in subjects with presumed MASH ⁵. ALG-097558 is a potential best-in-class small molecule coronavirus 3CL protease inhibitor (PI), which is at least 3-fold more potent in cell-based assays of coronavirus infection than other approved CoV PIs and is believed to be dosed twice daily without ritonavir co-dosing based on Phase 1 clinical studies ⁶.

For the fiscal year ended December 31, 2025, Aligos Therapeutics reported total revenue of $2,186 ⁷, a decrease from $3,945 ⁸ in the prior year. The company incurred a net loss of $24.2 million ⁹ for the year ended December 31, 2025, significantly lower than the net loss of $131.2 million ¹⁰ for the year ended December 31, 2024. As of December 31, 2025, the company had cash, cash equivalents, and short-term investments of $77.8 million ¹¹ and total stockholders' equity of $53.5 million ¹².

Research and development expenses decreased to $69,453 ¹³ for the year ended December 31, 2025, from $109,835 ¹⁴ in the prior year, representing a decrease of $40,382 ¹⁵ or 36.8% ¹⁶. General and administrative expenses also decreased to $19,372 ¹⁷ in 2025 from $25,321 ¹⁸ in 2024, a reduction of $5,949 ¹⁹ or 23.5% ²⁰. The change in fair value of 2023 Common Warrants resulted in a gain of $62,900 ²¹ in 2025, compared to a loss of $1,000 ²² in 2024.

During the year ended December 31, 2025, the company made a $9.0 million ²³ milestone payment to Emory University due to the first subject dosed in a Phase 2 clinical trial for pevifoscorvir sodium ²⁴. The Phase 2 B-SUPREME study for pevifoscorvir sodium initiated, and the first interim analysis is expected in the first half of 2026, with topline data anticipated in 2027 ²⁵. The Phase 2a HERALD study for ALG-055009 in MASH was completed in 2024, meeting its primary endpoint ²⁶. Preclinical activities for the coronavirus program were partially funded by grants from the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), with approximately $15.3 million ²⁷ in funds expected across these two awards and contracts ²⁸. An IND for the ALG-097558 program was submitted in the third quarter of 2024, and clinical studies in special populations were initiated in the second half of 2024 ²⁹.

Aligos Therapeutics expects to incur significant expenses and operating losses for the foreseeable future, as it has never generated revenue from product sales and does not anticipate doing so for the next several years, if ever ³⁰. The company will require substantial additional financing to achieve its goals, which may not be available on acceptable terms, or at all, and a failure to obtain this necessary capital could force delays, limitations, reductions, or termination of product development or commercialization efforts ³¹. Based on current research and development plans, existing cash, cash equivalents, and short-term investments are expected to fund operations into the third quarter of 2026 ³².

The company's primary growth area is the continued clinical development of its drug candidates. For chronic HBV infection, the Phase 2 B-SUPREME study for pevifoscorvir sodium is ongoing, with the first interim analysis expected in the first half of 2026 and topline data anticipated in 2027 ³³. This study aims to test the superiority of pevifoscorvir sodium monotherapy compared to tenofovir disoproxil fumarate over 48 weeks, with primary endpoints of HBV DNA <LLOQ (10 IU/mL, TD or TND) in HBeAg+ and HBeAg- subjects ³⁴. The company believes pevifoscorvir sodium has the potential to replace standard of care NAs and become the backbone of next-generation treatments, potentially contributing to higher rates of functional cure when combined with other mechanisms of action ³⁵. Additionally, the antisense oligonucleotide (ASO) platform for chronic HBV infection, including ALG-170675, is proceeding into IND-enabling studies, with current development costs in China funded by partner Xiamen Amoytop Biotech Co., Ltd. ³⁶. A novel ASO approach for hepatitis delta virus (HDV) coinfection is also in ongoing work for clinical development candidate selection ³⁷.

For MASH and obesity, the company is evaluating options to fund continued development of ALG-055009, including potential out-licensing ³⁸. Preclinical data suggest a significant benefit of adding ALG-055009 to incretin receptor agonist therapy for weight loss, especially in combination with low-dose tirzepatide, by mainly causing additional loss of fat mass without significant effect on lean mass or food consumption ³⁹. For coronavirus infections, ALG-097558 is in a Phase 2 clinical study in standard and high-risk COVID-19 patients, sponsored and performed by the AGILE University of Liverpool ⁴⁰. The company expects future development of ALG-097558 to be funded by external sources, including public funding, and anticipates receiving approximately $15.3 million ⁴¹ in funds across two NIH awards and contracts to support these activities ⁴². The projected efficacious dose range for SARS-CoV-2 is 200-600 mg ALG-097558 Q12H x 5 days, without the need for ritonavir coadministration ⁴³.

The company's operating expenses are expected to increase substantially due to ongoing clinical development activities for pevifoscorvir sodium ⁴⁴. The process of conducting nonclinical studies and clinical trials is costly and time-consuming, and the successful development of drug candidates is highly uncertain ⁴⁵. The company plans to finance its cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements, and other marketing or distribution arrangements ⁴⁶.

The company has identified structural headwinds and execution risks, including recurring losses from operations and negative cash flows, which raise substantial doubt about its ability to continue as a going concern ⁴⁷. The ability to raise additional funds depends on financial, economic, and other factors beyond its control, such as disruptions of global financial markets ⁴⁸. The company is also subject to the U.S. BIOSECURE Act, enacted in December 2025, which prohibits federal agencies from procuring biotechnology equipment or services from "biotechnology companies of concern," potentially restricting the ability of U.S. biopharmaceutical companies to purchase services or products from, or collaborate with, certain foreign CROs and CMOs ⁴⁹. This act has a grandfathering period of five years for existing contracts and carveouts for Medicaid and Medicare Part B drug supply, but its overall impact on the biotechnology industry is uncertain ⁵⁰.

The company faces material risks including recurring losses from operations and negative cash flows, which raise substantial doubt about its ability to continue as a going concern ⁵¹. The company will require substantial additional financing, which may not be available on acceptable terms, or at all, and a failure to obtain this capital could force delays, limits, reductions, or termination of product development or commercialization efforts ⁵². The U.S. BIOSECURE Act, enacted in December 2025, prohibits federal agencies from procuring biotechnology equipment or services from "biotechnology companies of concern," potentially restricting the company's ability to purchase services or collaborate with certain foreign CROs and CMOs, with an uncertain impact on the biotechnology industry ⁵³. The company is also exposed to significant competition from multinational pharmaceutical companies, established biotechnology companies, universities, and other research institutions, many of which have greater financial, technical, human, and other resources ⁵⁴. Regulatory risks include the lengthy, time-consuming, complex, and unpredictable approval processes of the FDA, EMA, and comparable foreign authorities, with no guarantee of obtaining regulatory approval for any drug candidate ⁵⁵. Furthermore, current and future healthcare reform legislation, such as the Inflation Reduction Act (IRA) enacted in 2022 and the One Big Beautiful Bill Act (OBBBA) enacted in July 2025, may increase the difficulty and cost of commercializing drug candidates, affect prices, and impose significant reductions in Medicaid program funding ⁵⁶. The IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, imposes rebates for price increases that outpace inflation, and redesigns the Medicare Part D benefit, with negotiated prices for initial drugs going into effect in 2026 and 2027 ⁵⁷. The OBBBA's reductions in Medicaid funding are expected to decrease enrollment and covered services, adversely affecting sales of commercialized drug candidates ⁵⁸.

Management emphasizes a strategy of developing pharmacologically optimized drug candidates to achieve improved treatment outcomes, focusing on liver and viral diseases where the team leverages in-depth knowledge and expertise ⁵⁹. Key strategic priorities include maximizing the value of current drug candidates by pursuing independent development and commercialization in select indications and markets, while opportunistically exploring additional licensing agreements, collaborations, or partnerships to accelerate development or commercialization in larger markets or specific geographies ⁶⁰. Another priority is expanding development capabilities and the pipeline through in-house discovery expertise to evaluate novel mechanisms of action and continually improve existing drug candidates, supplemented by actively evaluating external technology platforms and assets for future development candidates ⁶¹. Management also highlights the ongoing Phase 2 B-SUPREME study for pevifoscorvir sodium, with the first interim analysis expected in the first half of 2026 and topline data anticipated in 2027 ⁶². For ALG-055009, the company is evaluating options to fund continued development, including potential out-licensing ⁶³. For ALG-097558, future development is expected to be funded by external sources, including public funding, with approximately $15.3 million ⁶⁴ in funds expected from two NIH awards and contracts ⁶⁵.